Results 191 to 200 of about 767,524 (260)

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Fertility intentions among medical students in war-torn Ukraine: a cross-sectional survey. [PDF]

open access: yesBMC Public Health
Mogilevkina I   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy